Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Milnacipran Standard Review Sets Up Launch After Cymbalta In Fibromyalgia

This article was originally published in The Pink Sheet Daily

Executive Summary

Cypress Biosciences tells the DAILY it is optimistic about potential differentiation for fibromyalgia candidate, even if milnacipran will be the third drug to market for the condition.

You may also be interested in...



Lilly Wins Fibromyalgia Management Indication For Cymbalta

The blockbuster SNRI is second into the fibromyalgia space, following Pfizer’s Lyrica.

Lilly Wins Fibromyalgia Management Indication For Cymbalta

The blockbuster SNRI is second into the fibromyalgia space, following Pfizer’s Lyrica.

Fibromyalgia Patients Rate Lyrica High On Well-being Measures, Pfizer Says

Also at American Academy of Neurology meeting, UCB releases data on antiepileptic lacosamide.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel